Pharmaceutical Technology1 天
YTS-109 by Bristar Immunotech Biotechnology for Dermatomyositis: Likelihood of Approval
YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Dermatomyositis.